Return to homepagePandemic Pact

COVID19AM: Clinical study (COVIC-19) - Effectiveness of early transfusion of convalescent plasma with very high antibody concentrations in vulnerable patients with COVID-19 as a model for early therapy options in pandemic situations caused by new pathogens

  • Funded by Federal Ministry of Research, Technology and Space (BMFTR)
  • Total publications:3 publications

Grant number: 16LW0108

Grant search

Key facts

  • Disease

    COVID-19, Disease X

  • Start & end year

    2021
    2023

  • Known Financial Commitments (USD)

    $2,971,655.32

  • Funder

    Federal Ministry of Research, Technology and Space (BMFTR)

  • Research Location

    Germany

  • Lead Research Institution

    Deutsches Rotes Kreuz Blutspendedienst Baden-Württemberg - Hessen gemeinnützige Gesellschaft mit beschränkter Haftung

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

3 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

SARS-CoV-2 convalescent plasma for the controlled clinical trial "COVIC-19": Experience from collection of very high-titer plasma from superimmunized individuals.

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial.

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial.